截至2025年8月21日15时23分，康龙化成股价报30.01元，较前一交易日上涨0.40%。当日成交量为 336003手，成交金额达10.09亿元，振幅为2.31%。 康龙化成属于医疗服务板块，是一家提供药物研发外包服务的公司。公司业务涵盖药物发现、临床前及 临床研究服务等环节，为全球制药企业提供一体化研发服务。 公司8月21日晚间披露的2025年半年报显示，上半年实现营业收入64.41亿元，同比增长14.93%；归属于 上市公司股东的净利润7.01亿元，同比下降37%。公司表示净利润下滑主要由于上年同期处置 PROTEOLOGIX，INC.股权产生大额投资收益影响。 资金流向方面，8月21日主力资金净流出7581.73万元，近五日主力资金累计净流出30276.46万元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 ...

Core Viewpoint - The company is set to engage in daily related transactions with its affiliates for the year 2025, which are deemed necessary for normal business operations and will not harm the interests of the company or its shareholders [9][10]. Summary by Sections Related Party Transactions - The company has disclosed its related party transactions, including expected amounts and categories, with specific affiliates such as Beijing Bai'ao Pharmaceutical Co., Ltd. and Jiangsu Yong'an Pharmaceutical Co., Ltd. [1][3][4][5][6]. - The expected transaction amounts are calculated based on the company's projected expenditures or revenues for similar business activities in 2024 [1]. Performance and Compliance - The affiliates involved in the transactions have good credit and financial conditions, ensuring their ability to fulfill contractual obligations without creating bad debts for the company [2]. - The company will sign contracts with related parties for the expected daily transactions in 2025, ensuring legal protection for performance [2][8]. Pricing Policy - The pricing policy for related party transactions is based on fair and just principles, using market prices as a reference. Agreements are made voluntarily and equitably [7]. Purpose and Impact - The anticipated related transactions are essential for the company's operational needs, aimed at consolidating market presence, enhancing operational capabilities, and promoting profit growth. The transactions are structured to avoid dependency on related parties [9][10]. Approval Process - The expected related party transactions for 2025 have been approved by the company's board and will be submitted for shareholder approval [10][21]. Financial Indicators - The company reported a significant increase in R&D investment, amounting to 171.94 million yuan in 2024, representing a 39.02% increase from 2023, with R&D expenses accounting for 15.94% of total revenue [46]. Competitive Advantages - The company has established a comprehensive drug development service model, enhancing its ability to meet diverse client needs and improve the success rate of drug development [38][39]. - The company has developed specialized core technology clusters in high-difficulty research areas, providing a competitive edge in the market [39][40]. Client Relationships - The company has built strong client relationships through integrated drug development services, serving approximately 1,000 pharmaceutical enterprises, which enhances customer loyalty and supports future business growth [45]. Regulatory Compliance - The company has adhered to relevant laws and regulations regarding fundraising and the use of raised funds, ensuring compliance and protecting shareholder interests [49]. Management Changes - The company has undergone changes in its board of directors, including the resignation of an independent director and the nomination of a new candidate, ensuring compliance with governance requirements [51][52].